期刊文献+

不同抗血小板药物联合低分子肝素对糖尿病合并脑梗死的疗效 被引量:7

Comparison of therapeutic effects of different anti-platelet drugs combined low molecular weight heparin on patients with diabetes mellitus complicated cerebral infarction
下载PDF
导出
摘要 目的:比较糖尿病(T2DM)合并脑梗死(CI)患者应用不同抗血小板药物联合低分子肝素的临床疗效。方法:选择150例T2DM合并CI患者,分为:阿司匹林组,氯吡格雷组,奥扎格雷组,各50例,均同时给予低分子肝素治疗,疗程3个月。比较三组治疗后的临床疗效、神经功能缺损评分(NDS评分)、血小板计数(PLT)、凝血功能(PT、APTT、Fb)、各种不良反应发生率,以及随访1年的缺血性脑卒中再发率的差异。结果:奥扎格雷组总有效率明显低于阿司匹林组和氯吡格雷组(20.0%比62.0%、60.0%,P均<0.01),阿司匹林组和氯吡格雷组间无显著差异(P>0.05)。氯吡格雷组的NDS评分明显低于阿司匹林组和奥扎格雷组[(8.1±2.0)分比(16.2±3.4)分、(15.4±2.9)分,P均<0.05],阿司匹林组和奥扎格雷组无显著差异(P均>0.05)。三组的血小板计数(PLT)、凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)及纤维蛋白原(Fg)指标无显著差异(P均>0.05)。三组的不良反应发生率以及缺血性脑卒中再发率均无显著差异(P>0.05)。结论:与阿司匹林和奥扎格雷比较,氯吡格雷联合低分子肝素对于2型糖尿病合并脑梗死患者的临床疗效和神经功能改善最佳。 Objective:To compare the clinical therapeutic effects of different anti-platelet drugs combined low molec-ular weight heparin (LMWH ) on patients with type 2 diabetes mellitus (T2DM ) complicated cerebral infarction (CI) .Methods :A total of 150 patients with T2DM complicated CI were randomly and equally divided into aspirin group (received aspirin) ,clopidogrel group (received clopidogrel) and ozagrel group (received ozagrel) .All groups received LMWH simultaneously ,and were treated for three months .Therapeutic effects ,neurologic deficit score (NDS score) ,platelet count (PLT) ,coagulant function [prothrombin time (PT) ,activated partial thromboplastin time (APTT) ,fibrinogen (Fg)] ,incidence rates of adverse reactions and recurrence rates of ischemic cerebral stroke within one-year follow up were compared among three groups .Results:Total effective rate of ozagrel group was significantly lower than those of aspirin group and clopidogrel group (20.0% vs .62.0% ,60.0% , P〈 0.01 all) ,and there was no significant difference between aspirin group and clopidogrel group (P〉0.05) .NDS score of clopidogrel group was significant lower than those of aspirin group and ozagrel group [ (8.1 ± 2.0) scores vs .(16.2 ± 3.4) scores ,(15.4 ± 2.9) scores ,P〈0.05 all] ,and there was no significant difference between aspirin group and ozagrel group ( P〉0.05) .There were no significant difference in incidence rates of adverse reactions and recurrence rate of ischemic cerebral stroke and PLT ,PT ,APTT and Fg levels among three groups ( P〉0.05 all) .Conclusion:Compared with aspirin and ozagrel ,the clinical effect and neurologic function improvement of clopidogrel plus low molecular weight heparin is best in patients with type 2 diabetes mellitus complicated cerebral infarction .
作者 曹崇玉
出处 《心血管康复医学杂志》 CAS 2014年第5期556-559,共4页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 糖尿病 2型 脑梗塞 血小板聚集抑制剂 Diabetes mellitus, type 2 Brain infarction Platelet aggregation
  • 相关文献

参考文献9

  • 1OPDonnell MJ, Hankey GJ, Eikelboom JW. Antiplatelet therapy forseeondary prevention of noncardioembolic ischemic stroke: a critical review[J]. Stroke, 2008, 39 (5) : 1638- 1646.
  • 2Morales Vidal SG, Ruland S. Platelet antiaggregants in stroke prevention[J]. NeurolClin, 2013, 31 (3): 633-657.
  • 3SPS3 Investigators, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke [J:. N EnglJ Med, 2012, 367 (9): 817-825.
  • 4Li X, Zhou G, Zhou X, et al. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention follow ing TIA or stroke: A meta-analysis of randomized controlled trials [J]. J Neurol Sci, 2013, 332 (1-2): 92-96.
  • 5Reaume KT, Regal RE, Dorsch MP. Indications for dual anti- platelet therapy with aspirin and elopidogrel: evidence-based rec- ommendations for use [J]. Ann Pharmacother, 2008, 42 (4): 550-557.
  • 6White JR, Bettencourt-Silva JH, Potter J F, et al. Changes in an tiplatelet use prior to incident ischaemic stroke over 7 years in a UK centre and the association with stroke subtype [J]. Age Age- ing, 2013, 42 (5): 594-598.
  • 7Loke YK, White JR, Bettencourt-Silva JH, et al. Use of anti platelet drugs in stroke prevention: time for a rethink [J], Post- gradMedJ, 2013, 89 (1052): 309-310.
  • 8穆叶赛,阿木提,李国庆,阿不拉江,涂良珍.维、汉两族经皮冠状动脉介入术后使用氯吡格雷的安全性[J].心血管康复医学杂志,2012,21(1):58-60. 被引量:2
  • 9Maruyama H, Fukuoka T, Deguchi I, et al. Dual antiplatelet therapy clopidogrel with low-dose cilostazol intensifies platelet in- hibition in patients with ischemie stroke[J]. Intern Med, 2013, 52 (10): 1043-1047.

二级参考文献8

  • 1Falk E. Why do plaque rupture[J].Circulation, 1992, 86 (6 Suppl) : Ⅲ30-42.
  • 2StevenP,BrianP,EricJ编,陈灏珠译.心血管内科手册[M].北京:人民卫生出版社,2003,30-31.
  • 3Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) : a report of the American College of Cardiolo- gy/Americn Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous tran- suminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions [J]. J Am Coll Cardiol, 2001, 37 (8): 2239.
  • 4Popma JJ, Ohman EM, Weitz J, et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention [J]. Chest, 2001, 119 (1 Suppl): 321s-336s.
  • 5Mehta SR, Yusuf S, CURE Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design an baseline characteristics in- cluding a recta-analysis of the effects of thienopyridines in vascular disease[J].Eur Heart J, 2000, 21 (24): 2033-2041.
  • 6Chan AW, Moliterno DJ, Berger PB, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET) [J]. J Am Coll Cardiol, 2003, 42 (7): 1188-1195.
  • 7张新霞,段雯,魏文斌,张允奇,许香广,胡雪松.氯吡格雷对冠心病患者PCI前后CD40配体的影响[J].心血管康复医学杂志,2009,18(5):467-469. 被引量:6
  • 8孙黎,施安国.ADP受体阻滞剂的临床研究进展[J].中国临床药理学杂志,2002,18(4):306-309. 被引量:5

同被引文献55

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部